Thiazolidinedione 최신지견. (Korean)

Recent Perspective on Thiazolidinedione. (English)

Thiazolidinedione (TZD) is an insulin sensitizer that improves insulin resistance in the adipose tissue, liver, and muscles and has a pancreas-protective effect while inhibiting gluconeogenesis. Its other advantages include a glucose lowering effect, its durability, cardiovascular benefit, and recent evidence in nonalcoholic fatty liver disease and dementia. However, there are also concerns about fluid retention/ edema/heart failure, bladder cancer, and fractures with TZD use. TZD can still be a useful option for diabetes treatment when calculating risk versus benefit, but appropriate selection of patients is needed. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Korean Diabetes is the property of Korean Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)